AstraZeneca and Amgen’s Tezspire (tezepelumab) has demonstrated significant improvements in tissue inflammation and swallowing symptoms in patients with eosinophilic oesophagitis (EoE), with benefits sustained through 52 weeks in the phase 3 CROSSING trial. The study involved adolescents and adults with symptomatic EoE whose disease remained uncontrolled. Patients received Tezspire at 210mg or 420mg every four […]
The post Tezspire improves symptoms and tissue inflammation in phase 3 EoE trial appeared first on Pharmafile.